Arrestin-β-1 Physically Scaffolds TSH and IGF1 Receptors to Enable Crosstalk.
暂无分享,去创建一个
J. Banga | G. Kahaly | M. Gershengorn | S. Neumann | S. Morgan | J. Klubo-Gwiezdzinska | C. Krieger | Alisa Boutin | Daesong Jang | G. Kahaly | Sarah J. Morgan | J. Banga
[1] Alex R. B. Thomsen,et al. Therapeutic Targeting of Endosomal G-Protein-Coupled Receptors. , 2018, Trends in pharmacological sciences.
[2] J. Benovic,et al. Emerging Paradigm of Intracellular Targeting of G Protein-Coupled Receptors. , 2018, Trends in biochemical sciences.
[3] B. Marcus-Samuels,et al. Evidence That Graves' Ophthalmopathy Immunoglobulins Do Not Directly Activate IGF-1 Receptors. , 2018, Thyroid : official journal of the American Thyroid Association.
[4] G. Kahaly,et al. TSH/IGF-1 Receptor Cross-Talk Rapidly Activates Extracellular Signal-Regulated Kinases in Multiple Cell Types , 2017, Endocrinology.
[5] N. Suleymanova,et al. Enhanced response of melanoma cells to MEK inhibitors following unbiased IGF-1R down-regulation , 2017, Oncotarget.
[6] Y. Peterson,et al. The Diverse Roles of Arrestin Scaffolds in G Protein–Coupled Receptor Signaling , 2017, Pharmacological Reviews.
[7] G. Calin,et al. Functional antagonism of β-arrestin isoforms balance IGF-1R expression and signalling with distinct cancer-related biological outcomes , 2017, Oncogene.
[8] Terry J. Smith,et al. Teprotumumab for Thyroid‐Associated Ophthalmopathy , 2017, The New England journal of medicine.
[9] C. KriegerChristine,et al. TSHR/IGF-1R Cross-Talk, Not IGF-1R Stimulating Antibodies, Mediates Graves' Ophthalmopathy Pathogenesis. , 2017 .
[10] R. Place,et al. Inhibiting thyrotropin/insulin‐like growth factor 1 receptor crosstalk to treat Graves' ophthalmopathy: studies in orbital fibroblasts in vitro , 2017, British journal of pharmacology.
[11] A. Zelmer,et al. Visualization of Protein-protein Interaction in Nuclear and Cytoplasmic Fractions by Co-immunoprecipitation and In Situ Proximity Ligation Assay. , 2017, Journal of visualized experiments : JoVE.
[12] NeumannSusanne,et al. Thyrotropin and Insulin-Like Growth Factor 1 Receptor Crosstalk Upregulates Sodium–Iodide Symporter Expression in Primary Cultures of Human Thyrocytes , 2016 .
[13] R. Place,et al. TSH/IGF-1 Receptor Cross Talk in Graves' Ophthalmopathy Pathogenesis. , 2016, The Journal of clinical endocrinology and metabolism.
[14] W. Wiersinga,et al. The 2016 European Thyroid Association/European Group on Graves' Orbitopathy Guidelines for the Management of Graves' Orbitopathy , 2016, European Thyroid Journal.
[15] R. Bahn. Current Insights into the Pathogenesis of Graves’ Ophthalmopathy , 2015, Hormone and Metabolic Research.
[16] R. Place,et al. Bidirectional TSH and IGF-1 receptor cross talk mediates stimulation of hyaluronan secretion by Graves' disease immunoglobins. , 2015, The Journal of clinical endocrinology and metabolism.
[17] M. Gershengorn,et al. β‐Arrestin‐1 mediates thyrotropin‐enhanced osteoblast differentiation , 2014, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[18] A. Tee,et al. Possible targets for nonimmunosuppressive therapy of Graves' orbitopathy. , 2014, The Journal of clinical endocrinology and metabolism.
[19] L. Girnita,et al. β-Arrestin–biased agonism as the central mechanism of action for insulin-like growth factor 1 receptor–targeting antibodies in Ewing’s sarcoma , 2012, Proceedings of the National Academy of Sciences.
[20] Seema Kumar,et al. A stimulatory thyrotropin receptor antibody enhances hyaluronic acid synthesis in graves' orbital fibroblasts: inhibition by an IGF-I receptor blocking antibody. , 2012, The Journal of clinical endocrinology and metabolism.
[21] S. Pyne,et al. Receptor tyrosine kinase-G-protein-coupled receptor signalling platforms: out of the shadow? , 2011, Trends in pharmacological sciences.
[22] E. Rozengurt,et al. Crosstalk between Insulin/Insulin-like Growth Factor-1 Receptors and G Protein-Coupled Receptor Signaling Systems: A Novel Target for the Antidiabetic Drug Metformin in Pancreatic Cancer , 2010, Clinical Cancer Research.
[23] Aaron S. Gajadhar,et al. A proximity ligation assay using transiently transfected, epitope-tagged proteins: application for in situ detection of dimerized receptor tyrosine kinases. , 2010, BioTechniques.
[24] Terry J. Smith,et al. Evidence for an Association between Thyroid-Stimulating Hormone and Insulin-Like Growth Factor 1 Receptors: A Tale of Two Antigens Implicated in Graves’ Disease1 , 2008, The Journal of Immunology.
[25] P. Marin,et al. GPCR-jacking: from a new route in RTK signalling to a new concept in GPCR activation. , 2007, Trends in pharmacological sciences.
[26] Z. Goldsmith,et al. G Protein regulation of MAPK networks , 2007, Oncogene.
[27] D. Morrison,et al. Integrating signals from RTKs to ERK/MAPK , 2007, Oncogene.
[28] R. Paschke,et al. The Human Thyrotropin Receptor Is Predominantly Internalized by β-Arrestin 2 , 2006 .
[29] Terry J. Smith,et al. Monoclonal Pathogenic Antibodies to the Thyroid-Stimulating Hormone Receptor in Graves’ Disease with Potent Thyroid-Stimulating Activity but Differential Blocking Activity Activate Multiple Signaling Pathways1 , 2006, The Journal of Immunology.
[30] K. Siddle,et al. Grb10 and Grb14: enigmatic regulators of insulin action--and more? , 2005, The Biochemical journal.
[31] Robert J. Lefkowitz,et al. Transduction of Receptor Signals by ß-Arrestins , 2005, Science.
[32] Terry J. Smith,et al. Immunoglobulins from patients with Graves' disease induce hyaluronan synthesis in their orbital fibroblasts through the self-antigen, insulin-like growth factor-I receptor. , 2004, The Journal of clinical endocrinology and metabolism.
[33] T. Kohout,et al. β-Arrestin1 Mediates Insulin-like Growth Factor 1 (IGF-1) Activation of Phosphatidylinositol 3-Kinase (PI3K) and Anti-apoptosis* , 2003, Journal of Biological Chemistry.
[34] B. Calabretta,et al. Multiple Signaling Pathways of the Insulin-Like Growth Factor 1 Receptor in Protection from Apoptosis , 1999, Molecular and Cellular Biology.
[35] R. Lefkowitz,et al. β-Arrestins Regulate Mitogenic Signaling and Clathrin-mediated Endocytosis of the Insulin-like Growth Factor I Receptor* , 1998, The Journal of Biological Chemistry.
[36] B. Marcus-Samuels,et al. TSHR/IGF-1R Cross-Talk, Not IGF-1R Stimulating Antibodies, Mediates Graves' Ophthalmopathy Pathogenesis. , 2017, Thyroid : official journal of the American Thyroid Association.
[37] W. Dik,et al. Current perspectives on the role of orbital fibroblasts in the pathogenesis of Graves' ophthalmopathy. , 2016, Experimental eye research.
[38] Å. Wallén-Mackenzie,et al. In Situ Proximity Ligation Assay (PLA). , 2015, Methods in molecular biology.
[39] R. Bahn. Graves' ophthalmopathy. , 2010, The New England journal of medicine.